NEW YORK, Oct. 05, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Vitamin Shoppe, Inc. (NYSE:VSI) from March 1, 2017 through August 6, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Vitamin Shoppe investors under the federal securities laws.
To join the Vitamin Shoppe class action, go to http://rosenlegal.com/cases-1202.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Vitamin Shoppe’s retail segment was continuing to dramatically decline; (2) its ongoing “reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment and (3) Vitamin Shoppe was not properly recognizing that impairment charge; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1202.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 



